| 02.25.22 | The top IPOs of 2021; GSK slams brakes on RSV program; Sandoz launches Revlimid generic in Europe

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

2 jahre vor

Html
Text

This week's sponsor is Evidation.

WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST

Your roundup of the biggest and most popular stories from each of our publications.

Featured Story

GSK, in close race with Pfizer, slams brakes on phase 3 maternal RSV vaccine program over safety signal

By Nick Paul Taylor

GlaxoSmithKline has slammed the brakes on its pivotal maternal respiratory syncytial virus (RSV) vaccine program after a safety assessment, potentially handing an advantage to Pfizer in a close race to market.

Webinar: The Age of Digitization: Reimagining GxP and Non-GxP Asset Management

Wednesday, March 9, 2022 | 1pm ET / 10am PT

Modernizing your asset management strategy doesn’t have to be complicated. Join us to learn how the Connected Workplace for Life Sciences can help you support the full lifecycle of your assets, calibration, preventative maintenance, and vendor management all on one, validated platform. Register now.

Sandoz launches generic Revlimid in 19 countries in Europe, opening a flood of competition for BMS' megablockbuster

By Kevin Dunleavy

Sandoz has launched its generic version of Bristol Myers Squibb's multiple myeloma treatment Revlimid in 19 countries in Europe. German generics maker Stada Arzneimittel also has launched its Revlimid generic, according to reports.

The top 10 biotech IPOs of 2021

By Annalee Armstrong

The IPO market started off blazing hot in 2021, but valuations and interest began to cool toward the end of the year. We still saw a record-breaking 100 listings, with more and more companies filing for the public markets before producing even a shred of data.

The top 10 medtech IPOs of 2021

By Conor Hale

The second year of the COVID-19 pandemic saw a wave of global demand for coronavirus tests and telehealth that finally reached the public markets. But all waves ebb and flow, and many companies may have seen their stock value crest early in 2021.

Biotech IPOs in the current market environment? Experts say it's 'a bit silly, if not suicidal'

By Kyle LaHucik

2021 saw a rush of biotechs heading for the public markets, including companies seeking an initial public offering before ever producing a shred of clinical evidence. And they paid for it.

Sanofi, Regeneron ditch Dupixent trial in patients who failed Novartis and Roche's Xolair for hives condition

By Kevin Dunleavy

Sanofi and Regeneron have canned a trial of Dupixent in people with chronic spontaneous urticaria. The phase 3 study, which was stopped for futility, tested Dupixent in those who haven’t had success with the lone therapy approved for the condition—Novartis and Roche’s Xolair.

'Major blunder': Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update

By Fraiser Kansteiner

A slate of confidential witnesses have come forward to detail just how Bristol Myers dropped the ball on CAR-T drug Breyanzi's development. In a filing, they highlight the drugmaker’s myriad opportunities to rectify the situation before it was too late.

'Fantastic technology and a lousy company': Second Sight's 'bionic eyes' have gone obsolete while still implanted, report finds

By Andrea Park

Amid years of uncertainty, Second Sight's Argus II users say they’ve been left in the lurch, according to an investigation by IEEE Spectrum, which found that, with upgrades and repairs no longer available, many patients are merely counting the days until their vision-restoring implants go dark.

FDA grounds BioMarin gene therapy trial for months with demand for tumor risk data

By Nick Paul Taylor

BioMarin Pharmaceutical faces a long clinical hold on its phenylketonuria (PKU) gene therapy trial. After stopping the trial over tumors in mice, the FDA has asked BioMarin to run additional nonclinical studies that are expected to take “several quarters” to assess the risk of BMN 307.

Moderna taps Thermo Fisher for 15-year mRNA production pact for COVID vaccines and more

By Fraiser Kansteiner

Moderna and Thermo Fisher Scientific have forged a manufacturing pact to shore up production of Moderna’s COVID-19 vaccine Spikevax—plus the biotech’s other investigational mRNA products—over the next 15 years, the partners said Wednesday.

Oncologists on board for Novartis' prostate cancer radiotherapy, but logistics could hit uptake: survey

By Natalie Missakian

With the FDA set for a speedy review of Novartis’ new targeted radioligand therapy for a stubborn form of prostate cancer, a survey by Cardinal Health shows the drug is already winning favor with oncologists but also pointed to logistical challenges that could dampen its uptake.

How an OTC cough med could serve as a steppingstone for creating heart rhythm drugs

By Angus Liu

In the search for therapies against an inherited form of abnormal heart rhythm caused by certain mutations, scientists at Columbia University found a cough med could guide the development of future drugs for more common cardiac arrhythmias.

Webinar: How will Digital Medicine Improve the Delivery of Healthcare?

Thursday, March 3, 2022 | 12pm ET / 9am PT

Digital medicine is advancing pharmaceutical innovation, from creating digital therapeutics to more easily connecting with patients. This webinar will review key considerations and best practices in developing digital medicine, and how pharma organizations can create greater better outcomes with their pipeline and patients. Register now.